Abstract

Drugs can alter a victim’s perception and decision-making. Drug-facilitated crimes (DFCs) include drug-facilitated sexual assault (DFSA), robbery, murder, and drug trafficking. These drugs are typically disguised in alcoholic and non-alcoholic beverages and food and the majority of the cases included powerful central nervous system depressants. Drugs utilised in sexual assaults are frequently distributed at raves, dance clubs, and bars, but they are also being promoted at private gatherings. Pharmaceutical drugs, including benzodiazepines and their derivatives (such as zolpidem, zopiclone, or zaleplon), are implicated in over 60% of cases of DFC. Among these drugs, clonazepam (26%), zolpidem (16%), bromazepam (15%), histamine antagonists (8.2%), neuroleptics (3.9%), and anesthetics (specifically GHB and ketamine, which collectively account for 2.8% of the cases) are commonly employed in DFCS. This article aims to offer a comprehensive examination of the substances frequently employed to facilitate criminal behavior, together with an exploration of their underlying mechanisms of action.

• 1.   1. Garcia, M.G., Perez-Carceles, M.D., Osuna, E., & Legaz, I. (2021). Drug-facilitated sexual assault and other crimes: A systematic review by countries. Journal of Forensic and Legal Medicine, 79, 102151. https://doi. org/10.1016/j.jflm.2020.102151
• 2.   Shbair, M.K.S., & Lhermitte, M. (2010). Drugfacilitated crimes. Definitions, prevalence, difficulties, and recommendations: A review. Annales Pharmaceutiques Françaises, 68(3), 136–147. https://doi.org/10.1016/j. pharma.2010.02.006
• 3.   Volonnino, G., La Russa, R., Di Fazio, N., Ottaviani, M., Zamponi, M.V., Spadazzi, F., & Umani-Ronchi, F. (2023). Z-Drugs and their use in drug-facilitated crimes: A review of the literature. Clinica Terapeutica, 174(5), 451–456.
• 4.   Shbair, M.K.S., Eljabour, S., & Lhermitte, M. (2010). Drugs involved in drug-facilitated crimes. Part I: Alcohol, sedative-hypnotic drugs, gamma-hydroxybutyrate and ketamine. Annales Pharmaceutiques Françaises, 68, 275–285.
• 5.   Lemaire-Hurtel, A.S., & Alvarez, J.C. (2014). Drugs involved in drug-facilitated crime— Pharmacological aspects. In Forensic Toxicology: Drug Use and Misuse (Vol. 3, pp. 47–91).
• 6.  
• 7.   Schmitz, A. (2016). Benzodiazepine use, misuse, and abuse: A review. Mental Health Clinician, 6(3), 120–126. https://doi.org/10.9740/ mhc.2016.05.120
• 8.   Vincenti, F., Montesano, C., Babino, P., Carboni, S., Napoletano, S., De Sangro, G., ... & Sergi, M. (2021). Sensitive determination of benzodiazepine residues in drink and food paraphernalia by HPLC-HRMS/MS. Forensic Chemistry, 23, 100327.
• 9.   Griffin, C.E., Kaye, A.M., Bueno, F.R., & Kaye, A.D. (2013). Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner Journal, 13(2), 214–223.
• 10.   Bounds, C.G., Patel, P., & Nelson, V.L. (2024). Benzodiazepines. In StatPearls. StatPearls Publishing.
• 11.   Perez Orts, M., van Asten, A., & Kohler, I. (2023). The evolution toward designer benzodiazepines in drug-facilitated sexual assault cases. Journal of Analytical Toxicology, 47(1), 1–25. https://doi. org/10.1093/jat/bkac069.
• 12.   Orsolini, L., Chiappini, S., Grandinetti, P., Bruschi, A., Testa, R., Provenzano, A., ... & Volpe, U. (2021). ‘Z-trip’? A comprehensive overview and a case-series of Zolpidem misuse. Journal of Substance Use, 19(2), 367–387.
• 13.   Gunja, N. (2013). The clinical and forensic toxicology of Z-drugs. Medical Toxicology, 9(2), 155–162.
• 14.   Schifano, F., Chiappini, S., Corkery, J.M., & Guirguis, S. (2019). An insight into Z-drug abuse and dependence: An examination of reports to the European Medicines Agency database. International Journal of Neuropsychopharmacology, 22(4), 270–277.
• 15.   Drover, D.R. (2004). Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: Zaleplon, zolpidem and zopiclone. Clinical Pharmacokinetics, 43(4), 227–238.
• 16.   Dolder, C., Nelson, M., & McKinsey, J. (2007). Use of non-benzodiazepine hypnotics in the elderly: Are all agents the same? NS Drugs, 1(5), 389–405.
• 17.   Kenan, N., Mercan, S., & Acikkol, M. (2019). Development and validation of a practical analytical method for zolpidem as a drugfacilitated crime tool. Journal of Chemical Metrology, 13(2), 68–74.
• 18.   Zosel, A., Osterberg, E.C., & Mycyk, M. B. (2011). Zolpidem misuse with other medications or alcohol frequently results in intensive care unit admission. American Journal of Therapeutics, 18(4), 305–308.
• 19.   Rush, C.R. (1998). Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacology Biochemistry and Behavior,61(3), 253–269.
• 20.   Sanger, J.D., & Depoortere, H. (1998). The pharmacology and mechanism of action of zolpidem. CNS Drug Reviews, 4(4), 323–340.
• 21.   Gauthier, P., Arnaud, C., Stutzmann, J. M., & Gottesmann, C. (1998). Influence of zopiclone, a new generation hypnotic, on the intermediate stage and paradoxical sleep in the rat. Psychopharmacology (Berl), 130(2), 139–143.
• 22.   Jean Louis, C., Fernandez, B., Beaumont, C., Pinillos, M. A., Bardom, A., & Encina, Y. (2008). A case of zaleplon overdose. Clinical Toxicology (Philadelphia), 46(8), 782.
• 23.   Ebbens, M.M., & Verster, J.C. (2010). Clinical evaluation of zaleplon in the treatment of insomnia. Nature and Science of Sleep, 2, 115–126.
• 24.   Horstkötter, C., Schepmann, D., & Blaschke, G. (2003). Separation and identification of zaleplon metabolites in human urine using capillary electrophoresis and LC–MS. Journal of Chromatography A, 1014(1–2), 71–81.
• 25.   Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal, 4, 7107.
• 26.   Lee, T.S.H., Liu, Y.H., Huang, Y.J., Tang, W. K., Wang, Y., Hu, S., ... & Hung, C.C. (2022). Clinical and behavioral characteristics of individuals who used ketamine. Scientific Reports, 12(1), 801
• 27.   Li, J.H., Vicknasingam, B., Cheung, Y.W., Zhou, W., Nurhidayat, A.W., Des Jarlais, D. Clinical and behavioral characteristics of individuals who used ketamine. Scientific Reports, 12(1), 801
• 28.   Tay, E., Lo, W.K.W., & Murnion, B. (2022). Current insights on the impact of gammahydroxybutyrate (GHB) abuse. Substance Abuse: Research and Treatment, 13, 13–23.
• 29.   Busardò, F.P., & Jones, A.W. (2015). Gammahydroxybutyrate: Pharmacology and toxicology. Current Neuropharmacology, 13(1), 47–70.
• 30.   Kapoor, P., Deshmukh, R., & Kukreja, I. (2013). GHB acid: A rage or reprieve. Journal of Advanced Pharmaceutical Technology & Research, 4(4), 173–178.
• 31.   Sopuluchukwu, U.P., & Nnabuihe, E. D. (2021). A study on the neurotoxicity of flunitrazepam (Rohypnol) on the cerebral cortex of adult Wistar rats. Advances in Pharmacology and Pharmacy, 9(2), 26–32.
• 32.   Mattila, M.A., & Larni, H.M. (1980). Flunitrazepam: A review of its pharmacological properties and therapeutic use. Drugs, 20(5), 353–374.
• 33.   Jain, P., & Kanwal, N.K. (2018). A contemporary facet on Rohypnol: A date rape drug. MOJ Toxicology, 4(1), 1–3.

Data Sharing Statement

Funding